GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2008

Biodel Plans Manufacturing Facility for Injectable Insulin Product

  • Biodel reported plans to build and operate a fill and finish manufacturing facility for its Phase III injectable insulin product, VIAject™.

    Biodel anticipates that the site will cost under $15 million. The plant, to be located on the campus of Biodel’s headquarters in Danbury, CT, will be available for commercial production in 2009, according to the company.

    The firm  expects that the dedicated production plant will improve margins, provide superior quality control, and better inventory control.

    VIAject is Biodel’s lead candidate. It is being developed as a rapid-acting form of injectable human insulin for meal-time use by patients with type 1 or type 2 diabetes.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?